Home › Companies › RCUS

Arcus Biosciences

Market cap $2.36B 144.0M shares (10-Q, Oct 29, 2026) × $16.39 close Nov 17, 2026

Most recent annual filing: 2026-02-15

Catalyst timeline

7 trackedQuarter catalyst calendar →
  1. PEAK-1 / PEAK-20 enrollment doneYear-end 2026PEAK-1 / PEAK-20 enrollment done, Year-end 2026, notable
  2. I&I portfolio MRGPRX2 antagonist trialLate 2026 / Early 2027I&I portfolio MRGPRX2 antagonist trial, Late 2026 / Early 2027, routine
  3. quemliclustat Ph3 interim4Q 2026quemliclustat Ph3 interim, 4Q 2026, material
  4. ARC-20 cohorts cas+axitinib trial start4Q 2026ARC-20 cohorts cas+axitinib trial start, 4Q 2026, notable
  5. PEAK-20 trial start4Q 2026PEAK-20 trial start, 4Q 2026, notable
  6. PEAK-1 enrollment done4Q 2026PEAK-1 enrollment done, 4Q 2026, routine
  7. TNFR1 inhibitor RA trial startearly 2027TNFR1 inhibitor RA trial start, early 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (8 active programs)

Discontinued (3)

Capital (as filed)

Cash
$151M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$479M Sep 30, 2026
Long-term investments
$64.0M Sep 30, 2026
Operating cash flow
−$88.0M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$694M cash, runway 2029 per the update of Nov 4, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (11)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (11 calls)

Every verdict Biotech Distilled has published on Arcus Biosciences, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Arcus Biosciences (RCUS): Scientific Deep Dive for Casdatifan and Pipeline Products Casdatifan shows strong single-agent efficacy but unproven safety in IO combinations after the AstraZeneca trial pause, making RCUS a speculative turnaround play best watched until mid-2026 combination data arrives.
  2. Hold UPDATE: Arcus Biosciences (RCUS) - The Catalyst Wrap-Up Casdatifan single-agent efficacy is durable and management is pivoting to TKI-free combinations to avoid toxicity, but mid-2026 combination safety data is still needed before upgrading to BUY.
  3. Hold UPDATE: Arcus Biosciences (RCUS) - Gilead Walks Further Away, TIGIT Officially Dies, Stock Rips +25% TIGIT is fully dead removing R&D drag, casdatifan efficacy remains durable, and cash is fortress-like, but the mid-2026 combination safety data is still the trigger to upgrade to outright BUY; accumulate on dips into the mid-$20s.
  4. Hold UPDATE: Arcus Biosciences (RCUS) - The TKI-Free Bet Gets Its First Receipt eVOLVE-RCC02 is permanently buried, the TKI-free pivot has a first credible datapoint (7% primary progression in n=30), and I&I assets have clinic dates, but the mid-2026 cas+cabo ARC-20 readout remains the trigger to upgrade to outright BUY.
  5. Speculative buy speculative UPDATE: Arcus Biosciences (RCUS) - The Bispecific Bet Gets a Second Swing BMS stepping in with a PD-L1/VEGF-A bispecific restores front-line combination optionality lost with eVOLVE, the monotherapy-trap bear case keeps weakening, and the stock has pulled back to the low-$20s accumulation range, though the mid-2026 cas+cabo readout remains the gate to outright BUY.
  6. Speculative buy speculative UPDATE: Arcus Biosciences (RCUS) - Two More Partners in One Day, and the Backbone Pitch Stops Being a Pitch Two same-day partnerships (AVEO tivozanib randomized cohort and Summit ivonescimab) confirm casdatifan as a genuine backbone asset with five combination partners, but the mid-2026 cas+cabo ARC-20 data remains the gate to outright BUY and the stock at $29.97 has priced in much of the backbone thesis.
  7. Speculative buy speculative UPDATE: Arcus Biosciences (RCUS) - Gilead Leaves the Boardroom, the Trigger Slips to Fall PACIFIC-8 death removes last TIGIT drain, Gilead board exit reads as post-TIGIT housekeeping that simplifies M&A plumbing, PEAK-20 names the 1L bet, but the upgrade trigger slipped from mid-2026 to 2H 2026 with ≥18-month follow-up bar and the cas+zim+ipi safety read is a new gate.
  8. Buy core UPDATE: Arcus Biosciences (RCUS) - The Trigger Fires The cas+cabo ARC-20 trigger set in the original deep dive has fired: 14.5-month mPFS vs ~10 months for cabo alone and 77% vs ~60% 18-month OS, front-line data holds up, and PEAK-20 is on track, making the stock at $23.75 a de-risked Phase 1b dataset below its pre-data trading levels.
  9. Buy core UPDATE: Arcus Biosciences (RCUS) - The Dilution Gap Opens The clinical case is untouched after the offering announcement, the raise funds the three-Phase-3 plan rather than rescuing the balance sheet, but readers on the sidelines should let the deal price before acting given the fresh overhang.
  10. Buy core UPDATE: Arcus Biosciences (RCUS) - The Deal Prices, the Greenshoe Goes The offering priced at a tight 8.4% discount with the full greenshoe exercised, confirming real institutional demand; pro forma cash of ~$960M funds three registrational trials, and the condition to act for sidelined readers has been met.
  11. Buy core UPDATE: Arcus Biosciences (RCUS) - The Pancreas Gets a Date Casdatifan thesis is untouched and better funded with ~$960M pro forma cash and runway into 2029; Pfizer joining bispecific cohorts confirms backbone thesis; PRISM-1 interim moves into Q4 2026 adding a near-term binary but casdatifan still drives the valuation.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (33)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 5, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

3 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)